8-K: Perrigo Divests Dermacosmetics Business to KKR for Up to €327 Million, Streamlining Portfolio

Perrigo Company plc has signed an agreement to sell its Dermacosmetics branded business, including key brands ACO and Biodermal, to Kairos Bidco AB, an investment vehicle managed by KKR, for up to €327 million, advancing its strategic portfolio streamlining.

Summary

• Perrigo Company plc is divesting its Dermacosmetics branded business, which includes brands such as ACO, Biodermal, Emolium, and Iwostin, to Kairos Bidco AB, an investment vehicle managed by KKR & Co., Inc.
• The total consideration for the transaction is up to EUR 327 million, consisting of EUR 300 million in upfront cash and up to an additional EUR 27 million in contingent cash consideration.
• The contingent payment is tied to the achievement of specific net sales performance thresholds by the Dermacosmetics Business over a three-year period, covering financial years 2025, 2026, and 2027.
• In calendar year 2024, the Dermacosmetics branded business generated approximately EUR 125 million in net sales and contributed approximately 5% of Perrigo's adjusted operating income.
• The net proceeds from the transaction are expected to be directed towards strengthening Perrigo's balance sheet and supporting long-term value creation.
• The transaction is anticipated to close in the first quarter of 2026, pending the satisfaction of customary closing conditions, including regulatory approvals in certain jurisdictions and works council consultation procedures.

Sentiment

Score: 7

Explanation: The divestiture is a positive strategic move for Perrigo, aligning with its stated 'Three-S plan' and providing significant cash for balance sheet strengthening. While it reduces current revenue and operating income, the focus on core, high-growth areas is a long-term positive. The earn-out provides potential upside, and KKR's investment signals confidence in the divested assets. Risks are primarily related to closing conditions and general market factors, which are typical for such transactions.

Positives

• The divestiture aligns with Perrigo's 'Three-S plan' (Stabilize, Streamline, Strengthen) to focus on core, high-growth, and high-return opportunities within its self-care categories.
• The transaction provides a substantial upfront cash payment of EUR 300 million, which Perrigo intends to use for strengthening its balance sheet and supporting long-term value creation.
• Perrigo is entitled to additional contingent cash consideration of up to EUR 27 million, providing potential upside based on the future performance of the Dermacosmetics business.
• KKR's acquisition strategy focuses on 'resilient, growth-oriented consumer health platforms,' suggesting a positive outlook and dedicated investment for the divested Dermacosmetics brands under new ownership.

Negatives

• The divestiture will result in a reduction of Perrigo's overall revenue and adjusted operating income, as the Dermacosmetics business contributed approximately EUR 125 million in net sales and 5% of adjusted operating income in 2024.
• The contingent earn-out payments of up to EUR 27 million are not guaranteed and depend on the Dermacosmetics business achieving specific net sales performance thresholds over three years.
• The transaction is subject to several closing conditions, including regulatory approvals and works council consultations, which could potentially delay or prevent the successful completion of the sale.
• Perrigo will be obligated to provide certain transition services to Kairos post-closing and adhere to non-compete and non-solicitation agreements for a period of two years.

Risks

• Ability to complete the proposed divestment of the Dermacosmetics branded business.
• Receipt of works council and regulatory approval regarding the transaction.
• Performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction.
• Supply chain impacts on business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease.
• General economic, credit, and market conditions.
• Increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs).
• Impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions.
• Outbreak or escalation of conflict in other regions where business is conducted, including the Middle East.
• Current and future impairment charges, if the carrying amount of specific assets may not be recoverable from expected future cash flows.
• Customer acceptance of new products.
• Competition from other industry participants, some of whom have greater marketing resources or larger market shares.
• Pricing pressures from customers and consumers.
• Resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives.
• Uncertainty regarding ability to obtain and maintain regulatory approvals.
• Potential costs and reputational impact of product recalls or sales halts.
• Potential adverse changes to U.S. and foreign tax, healthcare and other government policy.
• The effect of epidemic or pandemic disease.
• The timing, amount and cost of any share repurchases and/or any refinancing of outstanding debt at or prior to maturity.
• Fluctuations in currency exchange rates and interest rates.
• Receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business and the Hospital and Specialty Business, and the risk that potential costs or liabilities incurred or retained may exceed estimates.
• The risk that potential costs or liabilities incurred or retained in connection with the sale of the Rx business may exceed estimates or adversely affect business or operations.
• The consummation and success of other announced and unannounced acquisitions or dispositions, and the ability to realize the desired benefits thereof.
• Ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including ongoing restructuring programs.
• Adverse results with respect to pending litigation could have a material adverse impact on operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages.

Future Outlook

Perrigo anticipates that this divestiture will significantly advance its 'Three-S plan' by enabling a sharper focus on its core self-care categories, which are identified as high-growth and high-return opportunities. The net proceeds from the transaction are earmarked for strengthening the company's balance sheet and fostering long-term value creation. The Dermacosmetics business is expected to flourish under KKR's ownership, benefiting from dedicated strategic focus and investment, aligning with KKR's established investment approach in the consumer health sector.

Management Comments

• "This proposed transaction marks another significant milestone in the execution of our Three-S plan. By sharpening our focus on core self-care categories that align with our One Perrigo model, we are enhancing our ability to drive sustainable growth and deliver greater value to consumers, customers and shareholders." Patrick Lockwood-Taylor, President and Chief Executive Officer.
• "We believe these brands are well-positioned to thrive under new ownership, where they can benefit from dedicated focus and investment." Patrick Lockwood-Taylor, President and Chief Executive Officer.
• "We are pleased to announce this proposed acquisition of Perrigo’s Dermacosmetics business, home to trusted brands and high-quality products. We’ve been impressed by the talented team behind its success and the strong and loyal market reputation they’ve built. This acquisition aligns with KKR’s strategy of investing in resilient, growth-oriented consumer health platforms. We look forward to working closely with the management team to accelerate growth by leveraging our global network, operational expertise, and long-term capital unlocking lasting value in this dynamic and important sector." Iñaki Cobo, Partner at KKR.

Industry Context

This divestiture by Perrigo aligns with a broader industry trend among diversified pharmaceutical and consumer health companies to streamline their portfolios, focusing on core, higher-growth segments to enhance efficiency and profitability. Perrigo's 'Three-S plan' is a strategic response to market dynamics, aiming to reallocate capital to its primary over-the-counter (OTC) self-care business. KKR's acquisition of the Dermacosmetics business, following its proposed acquisition of Karo Healthcare, underscores a strong private equity interest in the resilient and growing consumer health and beauty products sector, particularly for established brands with strong market positions. This transaction allows Perrigo to concentrate on its 'One Perrigo model' while KKR expands its specialized consumer health portfolio.

Comparison to Industry Standards

• The implied revenue multiple of approximately 2.6x (EUR 327 million consideration / EUR 125 million 2024 net sales) for the Dermacosmetics business is generally within the typical range for divestitures in the consumer health and beauty sector, although specific comparable deals would require more detailed market data for a precise assessment.
• KKR's stated investment strategy of targeting 'resilient, growth-oriented consumer health platforms' is consistent with its recent acquisitions and investments in category leaders such as The Bountiful Company, Wella Company, Coty, Vini Cosmetics, KDC/ONE, and Arnotts Group, and the pending acquisition of Karo Healthcare, indicating a strategic fit for the Dermacosmetics business within KKR's existing portfolio.
• The inclusion of earn-out provisions, allowing for up to EUR 27 million in contingent payments, is a common practice in M&A transactions, particularly for businesses with identifiable growth potential, as it enables the seller to participate in future upside while mitigating upfront valuation risk for the buyer.
• The extensive list of closing conditions, including various regulatory approvals (merger and investment control) and works council consultations, is standard for complex cross-border divestitures involving European operations, reflecting the stringent regulatory environment in these regions.

Corporate Governance

Legal Proceedings

• Resolution of uncertain tax positions and any litigation relating thereto is identified as a risk factor.
• Ongoing or future government investigations and regulatory initiatives are noted as potential challenges.
• Potential costs and reputational impact of product recalls or sales halts are mentioned as risks.
• Adverse results with respect to pending litigation could have a material adverse impact on operating results, cash flows, and liquidity, potentially requiring the use of corporate assets to pay damages.
• Accruals and provisions for outstanding severance payments and any accrual, reserve or other liability related to any pending litigation or legal action are included in the calculation of Closing Date Financial Debt.

Related Party Transactions

• The Nordics Reorganization involves the termination of intercompany agreements between Perrigo Group companies and the Share Deal Entities.
• Certain assets, liabilities, and employees are being carved in/out between RemainCo and Share Deal Entities at fair market value (or tax book value under specific conditions) as part of the Nordics Reorganization.
• Any short-term receivables and/or short-term liabilities entered into or settled between Perrigo Group companies in connection with the Nordics Reorganization will be non-interest bearing.

Stakeholder Impact

• Shareholders: Expected to benefit from Perrigo's sharpened strategic focus on core self-care categories, potential for long-term sustainable growth, and strengthening of the balance sheet through transaction proceeds.
• Employees: 'Silver Employees' (directors, officers, and employees essential for the Sold Business) will transfer to the Purchaser or its affiliates. Works council consultation procedures are a condition for closing, ensuring employee representation is involved. Perrigo indemnifies the Purchaser for 'Retained Employees' who might allege transfer, mitigating risk for the buyer.
• Customers: The Dermacosmetics brands (ACO, Biodermal, Emolium, Iwostin) are expected to continue to thrive under KKR's ownership, potentially benefiting from dedicated focus and investment, which could lead to enhanced product offerings and market presence.
• Suppliers: Existing supply agreements related to the Dermacosmetics business will be transferred or managed during a transition period, ensuring continuity of operations for the divested business.
• Creditors: Proceeds from the sale are intended to strengthen Perrigo's balance sheet, which could improve its financial position and creditworthiness, potentially benefiting creditors.

Next Steps

• Perrigo and Kairos Bidco AB must work towards satisfying customary closing conditions, including obtaining regulatory approvals in Finland, Poland, Norway, and Sweden (merger control) and Sweden (investment control).
• Completion of pre-closing restructuring transactions with respect to Aco Hud Nordic AB is required.
• Completion of works council consultation procedures in certain countries, particularly the Netherlands, must occur.
• The closing of KKR's previously announced proposed acquisition of Karo Healthcare (Project Everyday Closing) is a prerequisite.
• Perrigo will provide certain transition services to Kairos after the transaction closes.
• The performance of the Dermacosmetics Business will be monitored over a three-year period (FY 2025, 2026, 2027) to determine any earn-out payments.
• The Purchaser is obligated to cease using Perrigo's corporate brands within specified transition periods post-closing.
• The Purchaser must ensure compliance with non-compete and non-solicitation agreements for two years following the closing date.

Key Dates

Recommendation

Keywords

Perrigo, Divestiture, Dermacosmetics, KKR, Kairos Bidco AB, Self-Care Products, Consumer Health, Strategic Focus, Asset Sale, Aco Hud Nordic AB, ACO Brand, Biodermal Brand, Emolium, Iwostin, SEC Filing, 8-K, Merger Control, Works Council, Earn-Out, Balance Sheet Strengthening, Portfolio Streamlining